NetScientific PLC (LON:NSCI) said investee company Glycotest Inc has received a second US$3mln tranche of its US$10mln Series A fundraising round with China’s Fosun Pharmaceutical.
The cash injection will allow Glycotest to advance towards commercial launch its algorithm-driven test for hepatocellular carcinoma, a form of liver cancer.
“We are proud to be supporters of Glycotest who we believe has the strong potential to deliver value for our shareholders,” said NetScientific chief executive Ian Postlethwaite.